Decreased levels of urinary liver-type fatty acid-binding protein after switching from tenofovir disoproxil fumarate to tenofovir alafenamide: a prospective observational study

A single-center, prospective, observational study was conducted between September 2016 and August 2018 in 33 HIV-positive Japanese patients who switched antiretroviral drug regimens from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF). The study assessed changes in urinary levels...

Full description

Saved in:
Bibliographic Details
Published in:International journal of STD & AIDS 2019-11, Vol.30 (13), p.1311-1317
Main Authors: Hikasa, Shinichi, Shimabukuro, Shota, Hideta, Kyoko, Nishida, Sakurako, Higasa, Satoshi, Sawada, Akihiro, Tokugawa, Tazuko, Tanaka, Kuniyoshi, Yanai, Mina, Kimura, Takeshi
Format: Article
Language:English
Subjects:
Adenine - analogs & derivatives
Adenine - therapeutic use
Adult
Anti-HIV Agents - therapeutic use
Antiviral Agents - administration & dosage
Antiviral Agents - therapeutic use
beta 2-Microglobulin - urine
Biomarkers - urine
CD4 Lymphocyte Count
Creatinine - urine
Fatty Acid-Binding Proteins
Female
Glomerular Filtration Rate - drug effects
Glomerular Filtration Rate - physiology
HIV Infections - drug therapy
HIV Infections - urine
Humans
Male
Middle Aged
Prospective Studies
Tenofovir - therapeutic use
Treatment Outcome
Viral Load - drug effects
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A single-center, prospective, observational study was conducted between September 2016 and August 2018 in 33 HIV-positive Japanese patients who switched antiretroviral drug regimens from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF). The study assessed changes in urinary levels of liver-type fatty acid-binding protein (L-FABP) after switching from TDF to TAF and determined the potential of renal parameters to predict improvement in estimated glomerular filtration rate (eGFR). Median urinary levels of L-FABP were found to be 2.0, 1.4, and 1.3 µg/g creatinine before, at 6 months, and at 12 months after switching to TAF, respectively. The urinary levels of L-FABP, β2 microglobulin (β2MG), and eGFR and the protein-to-creatinine ratio (PCR) were not significantly related to the annual change in eGFR after switching from TDF to TAF. Our results demonstrate a significant decrease in urinary levels of L-FABP after switching from TDF to TAF. However, neither urinary L-FABP, β2MG, PCR, nor eGFR predicted the annual change in eGFR after the change in medication.
ISSN:0956-4624
1758-1052
DOI:10.1177/0956462419873772